Nutex Health Inc

In Stage 2 advancing environment, NUTX maintains a medium-term bullish bias despite recent support failure at the $173 zone and early momentum loss. Price remains above the rising 50 DMA, anchoring upside potential, while 9/21 EMAs cap rallies, indicating caution. Short-term timing is unfavorable for entries as price trades below falling EMAs with distribution pressure evident. We recommend stalking for a disciplined re-entry into the uptrend near structural support, awaiting a clean pullback into the rising 50 DMA or reclaim of the 9/21 EMA zone to confirm resumption.

• ↑Q1 2025 revenue grew 214% YoY to $211.8M; adjusted EBITDA $72.8M
• ↑Arbitration drives 71% of hospital revenue with >85% win rate for cash predictability
• ↓Dependence on arbitration under IDR exposes revenue to potential regulatory reversals; $55M cut last cycle